|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
The fund follows the return seasonality strategy by investing into stocks with exceptionally high or low returns during the same-calendar-months. Monthly rebalancing, thus the fund closes its position.
Portfolio consists of 20 biotechnology/pharmaceutical corporations' stocks. Equal weighting | Passive buy and hold strategy, long term.
Incyte corporation is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Its beta is 0.95 which is slightly under the market beta. Earnings are forecast to grow 27,55% per year. So the company is good and stable, but still have great growing situation.